DelfaGLP-1 Atlas

Lead sponsor

Xiangya Hospital of Central South University

6 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

6

Trials led

0

Active

888

Total enrollment

1

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 2
1
Phase 3
5

Trials by status

Withdrawn
1
Unknown
5

Trials led

Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbiditiesBMI ≥30Ph 3Unknown300
Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbiditiesBMI ≥30Ph 3Unknown300
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese PatientsBMI ≥28Ph 3Unknown150
Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin TherapyHbA1c ≥9%Ph 3Unknown78
Effects of Benaglutide on Weight and Gut Microbiota in Obese PatientsBMI ≥28Ph 3Unknown60
The Effect and the Pharmacogenomics Study of Liraglutide in Obese PatientsBMI ≥28Ph 2Withdrawnnot disclosed